Pulse Biosciences, Inc.
Pulse Biosciences, Inc.
Your view on PLSE
Overview
What the company does, where it operates, and who runs it.
About Pulse Biosciences, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Paul Arthur LaViolette
- Headquarters
- 3957 Point Eden Way, Miami, CA, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Paul Arthur LaViolette
- Headquarters
- 3957 Point Eden Way, Miami, CA, US
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Pulse Biosciences, Inc., and the rating behind it. PLSE last traded at $53.11; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Pulse Biosciences, Inc.. Starting points for Pulse Biosciences, Inc.: EPS -$1.16, beta 1.63 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Pulse Biosciences, Inc.. Pulse Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Pulse Biosciences, Inc.. Trailing twelve-month EPS for Pulse Biosciences, Inc. stands at -$1.16. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Pulse Biosciences, Inc.. Pulse Biosciences, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Pulse Biosciences, Inc. valued side by side against its closest peers. Pulse Biosciences, Inc. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Pulse Biosciences, Inc., and how their positions are changing. At a $3.68B market value, institutional positions materially move Pulse Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Pulse Biosciences, Inc. executives and directors. Shares of Pulse Biosciences, Inc. have traded between $12.93 and $25.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Pulse Biosciences, Inc.. Pulse Biosciences, Inc. is a $3.68B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Pulse Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Pulse Biosciences, Inc.. Coverage tracks Pulse Biosciences, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.